Stockscreener 앱 받기
15.80
1.34%
-0.26
Kalvista Pharmaceuticals Inc 주식(KALV)의 최신 뉴스
KalVista Pharmaceuticals Presents New Data Highlighting High Patient Satisfaction and Evolving Treatment Trends with EKTERLY® (sebetralstat) - BioSpace
KalVista presents sebetralstat data showing early treatment impact By Investing.com - Investing.com India
Market Trends: How does KalVista Pharmaceuticals Inc perform in inflationary periodsWatch List & Low Risk Growth Stock Ideas - baoquankhu1.vn
KalVista Pharmaceuticals, Inc. (KALV): Investor Outlook with a Promising 115% Upside Potential - DirectorsTalk Interviews
Ekterly use urged for kids with HAE 12 and older in new international guideline - Angioedema News
How Kalvista Pharmaceuticals Inc. (KALV) Affects Rotational Strategy Timing - Stock Traders Daily
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences - The Joplin Globe
KalVista Pharma chief development officer sells $67,668 in stock - Investing.com
KalVista Pharma CCO Sweeny Sold $61,878 in Stock - Investing.com UK
Kalvista Pharma CFO Piekos sells $27,506 in shares By Investing.com - Investing.com Australia
Insider Selling: KalVista Pharmaceuticals (NASDAQ:KALV) Insider Sells 5,354 Shares of Stock - MarketBeat
KalVista Pharmaceuticals (NASDAQ:KALV) CEO Benjamin Palleiko Sells 10,034 Shares - MarketBeat
KalVista Pharmaceuticals (NASDAQ:KALV) Insider Sells $61,890.75 in Stock - MarketBeat
KalVista Pharma CMO Audhya sells $83k in shares By Investing.com - Investing.com South Africa
Kalvista Pharma CEO Palleiko sells $156k in shares to cover tax obligations - Investing.com Australia
KalVista Pharma chief development officer sells $67,668 in stock By Investing.com - Investing.com Canada
Kalvista Pharma CFO Piekos sells $27,506 in shares - Investing.com
KalVista Pharma CMO Audhya sells $83k in shares - Investing.com India
[Form 4] KalVista Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
KalVista (NASDAQ: KALV) CFO details RSU vesting and sell-to-cover sale - Stock Titan
KalVista Pharma CCO Sweeny Sold $61,878 in Stock By Investing.com - Investing.com UK
Wall Street Analysts Think KalVista Pharmaceuticals (KALV) Could Surge 117.1%: Read This Before Placing a Bet - Finviz
Skandinaviska Enskilda Banken AB publ Buys 160,128 Shares of KalVista Pharmaceuticals, Inc. $KALV - MarketBeat
Analysts Offer Insights on Healthcare Companies: KalVista Pharmaceuticals (KALV), Bausch Health Companies (BHC) and Insulet (PODD) - The Globe and Mail
KalVista Pharmaceuticals, Inc. (KALV) Stock Analysis: Investors Eye 113.97% Potential Upside - DirectorsTalk Interviews
Insider Selling: KalVista Pharmaceuticals (NASDAQ:KALV) CEO Sells 1,038 Shares of Stock - MarketBeat
KalVista's Ekterly Recommended as First-Line Treatment for HAE i - GuruFocus
International guideline recommends EKTERLY as first-line HAE therapy - Investing.com Nigeria
International guideline recommends EKTERLY as first-line HAE therapy By Investing.com - Investing.com Australia
KalVista Pharmaceuticals Announces Inclusion of EKTERLY® (sebetralstat) as a First-Line Therapy for Adolescents 12 and Older in International Pediatric HAE Guideline - BioSpace
KalVista Pharmaceuticals Announces Inclusion of EKTERLY® (sebetralstat) as a First-Line Therapy for - PharmiWeb.com
KalVista's Ekterly Recommended as First-Line Treatment for HAE in Adolescents - GuruFocus
KalVista Pharmaceuticals (KALV) Leads in Short Interest Among Bi - GuruFocus
Hereditary Angioedema Clinical Trial Pipeline Expands as 20+ - openPR.com
KalVista (KALV) and Intellia (NTLA) Lead Short Interest Surge in Small-Cap Biotech - GuruFocus
KalVista Pharmaceuticals Q3 2026 Earnings Preview - MSN
(KALV) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Will KalVista Pharmaceuticals Inc. face regulatory challengesMarket Sentiment Review & Daily Stock Trend Reports - mfd.ru
Benjamin Palleiko Sells 3,354 Shares of KalVista Pharmaceuticals (NASDAQ:KALV) Stock - MarketBeat
Will KalVista Pharmaceuticals Inc. stock benefit from automationJuly 2025 Retail & Weekly High Return Forecasts - mfd.ru
KalVista Pharmaceuticals (KALV) Stock Analysis: Unpacking A 123% Potential Upside - DirectorsTalk Interviews
Hereditary Angioedema Market to Surpass USD 3 Billion Baseline in 2023, Set for Robust Growth Through 2034 Across 7MM with 7,000 Diagnosed US Cases | DelveInsight - Barchart.com
KalVista Pharmaceuticals to Present EKTERLY® (sebetralstat) Data at the 2026 American Academy of All - pharmiweb.com
KalVista Pharmaceuticals to Present EKTERLY® (sebetralstat) Data at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting - BioSpace
(sebetralstat) Data at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting - Business Wire
Travel Stocks: Should I hold or sell KalVista Pharmaceuticals Inc nowM&A Rumor & Technical Confirmation Alerts - baoquankhu1.vn
KalVista: Next Stage Of Growth For EKTERLY Lies With Pediatric Label Expansion (KALV) - Seeking Alpha
Is KalVista Pharmaceuticals Inc. a turnaround storyMarket Risk Report & Momentum Based Trading Signals - mfd.ru
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - 富途牛牛
Market Catalysts: Does Global Blue Group Holding AG Equity Warrant have a sustainable dividendTrend Reversal & Safe Capital Preservation Plans - baoquankhu1.vn
KalVista Pharmaceuticals sees $1.5m stock purchase by Venrock - MSN
Responsive Playbooks and the KALV Inflection - Stock Traders Daily
Aug Sentiment: Is KalVista Pharmaceuticals Inc subject to activist investor interestPortfolio Value Report & Expert-Curated Trade Recommendations - baoquankhu1.vn
1.19%
1.03%
자본화:
|
볼륨(24시간):